Outcomes
MEASLES, EVENT, SECONDARY, MUMPS, RUBELLA
The primary outcome assessed was seroconversion (being seronegative at baseline and seropositive post-vaccination) to the antigens in the vaccines received at the baseline visit. A secondary outcome assessed antibody levels post-vaccination, defined as IgG antibody concentrations for measles, mumps, and rubella and neutralizing antibody titers for YF, to the antigens in the vaccines received at the baseline visit. Additional secondary outcomes included seroconversion and antibody levels following MMR and YF vaccines received at Visit 2. The cut-offs used for seropositivity were as follows: measles concentrations > 150 mIU/ml; rubella concentrations > 4 IU/ml; mumps concentrations ≥ 231 U/ml; and YF PRNTAdverse event monitoring followed national guidelines and classification criteria described elsewhere [